A thread for every name
Each company on the Catalyst List gets its own thread, plus a General board. Open a name and the pinned summary shows the catalyst, the date, the cash runway and a link to the filing it came from.
What the room does
An AI Moderator in every thread
It hosts each ticker thread and answers questions addressed to it using only that company's verified data. It is always labeled AI.
Specialists who read the filings
Ask a question and it goes to the right specialist, or pick one yourself. They answer from the list and the cited filings, quote the source, and say so when they don't know.
Information only
Nothing here is investment advice. Members share their own views, and the AI specialists are built never to tell you what to buy or sell.
Community guidelines apply: keep it civil and on topic, and no promotion. Posts are screened automatically, and a person makes any final call on bans. Guidelines
Meet the specialists
Seven AI specialists plus a general Expert. Each one is labeled AI and answers only from the verified list and its source filings.
- OncologyTrial design, endpoints, and what an interim or topline readout actually measures.
- Neurology & psychiatryCNS trials, placebo response and endpoint quirks.
- Immunology & inflammationAutoimmune, dermatology and respiratory programs.
- Cardio, metabolic & liverObesity, diabetes, MASH and kidney programs.
- Rare disease & geneticGene therapy, orphan drugs and small-trial designs.
- Regulatory & PDUFAWhat a PDUFA date, complete response letter or accelerated approval means, from each company's own filings.
- Balance sheet & financingCash runway, dilution, going-concern language, at-the-market offerings and reverse splits.
How an answer looks
An illustrative example using a real row from the list. Live answers will follow this pattern.
Member
@Expert What does Apnimed say about its cash runway?
Balance sheet specialist AI
At 30 June 2026 Apnimed reported $172.8M in cash and equivalents, plus IPO proceeds. The company states this is sufficient to fund operations for at least twelve months from the 10-Q issuance date. Its FDA decision date for AD109 is 28 February 2027.
Source: 8-K EX-99.1 (Q2 2026 results), sec.gov. Information only, not advice.
Member
@Expert So should I buy it before the decision?
Regulatory specialist AI
I can't say whether to buy, sell or hold any stock, or which way a price might move. I can explain how a PDUFA review works, what the company has disclosed about the AD109 application, or where the risks it names are described in its filing. Which would help?
Information only, not advice.
What it will not do
- Tell anyone to buy, sell, short or hold a security
- Predict prices or say a stock is a good or bad investment
- Use inside information or anything outside the filings and the verified list
- Give personalised guidance based on your portfolio
The room is open to invited members
Chat 2.0 is open now to people we have invited. Public subscriptions (monthly $5 or annual $45) open soon: join the waitlist on the home page to hear first.
Get AccessComing Soon Enter the room